Georgia Life Sciences Statement on U.S. Tariff Announcement

Updates: Since this statement was made, the administration announced, April 9, a 90-day pause on reciprocal tariffs. See the AdvaMed  CEO statement on this change. GLS aligns with this statement.


April 3, 2025

The recent U.S. tariff announcement has sent ripples through the life sciences, biotech, and MedTech industries, raising concerns about its potential impact on innovation, manufacturing, and global supply chains. While some sectors, such as pharmaceuticals, have been temporarily exempt from these new tariffs, the uncertainty surrounding future trade policies remains a significant challenge for our industry.

 

These tariffs—set to take effect on April 5—include a base 10% tariff on all countries, with reciprocal tariffs reaching up to 50% on certain nations. There are growing concerns that these measures could increase costs for life-saving medical technologies, disrupt supply chains, and hinder job growth. Additionally, the agricultural biotech sector will likely be affected immediately, particularly with higher tariffs on non-USMCA-compliant goods. Pharmaceuticals, while currently exempt, may face their own tariffs in the near future, pending a potential Section 232 investigation into pharmaceutical manufacturing and national security.

 

Georgia’s life sciences ecosystem thrives on innovation, investment, and global collaboration. Our industry depends on stable, predictable trade policies that support growth, not policies that introduce uncertainty and additional financial burdens. We must ensure that trade policies protect patients, support manufacturers, and sustain the broader biotech and MedTech economy.

 

Georgia Life Sciences will continue to monitor these developments in partnership with our national associations and work closely with our members and policymakers to ensure our industry’s voice is heard. We encourage our community to stay engaged and share any concerns about how these tariffs may impact your businesses, workforce, and supply chains.

 

For questions or to provide input on how these policies affect your organization, please reach out to our team.

Who will be Presenting at the Georgia Life Sciences Summit Startup Showcase

August 6, 2026
From breakthrough therapeutics to next-generation medical technologies, tomorrow's innovators take the stage at the Georgia Life Sciences Summit. Sponsored by Johnson & Johnson, the Startup Showcase will highlight eight of Georgia's most promising early-stage life sciences companies as they present their innovations during the Summit Luncheon on August 26. These emerging companies are tackling some of healthcare's biggest challenges across therapeutics, diagnostics, AI, and medical technology, while demonstrating the depth of innovation taking place throughout Georgia's life sciences ecosystem. Meet the 2026 Startup Showcase Companies: Abundance Biopharma Corporation Athna Biotech Atomistic Insights NovAb Nytricx Oridivus TremeBio YoungHeartValve Following the presentations, each company will participate in a live investor Q&A featuring an exceptional panel of venture leaders: Emily Dinu, Numinous Capital John Gutierrez, Ascenta Capital Dr. Emma Heckenberg, Solas BioVentures Patrick Jordan, NovaQuest Capital Management Tim Opler, Stifel Whether you're an investor looking for the next breakthrough, a corporate leader seeking innovative partners, or simply interested in the future of life sciences, the Startup Showcase offers a front-row seat to the companies poised to shape what's next. Join us August 25–26 at the Georgia Life Sciences Summit and discover the next generation of innovators driving Georgia's life sciences economy.

Georgia Life Sciences Applauds Congressman McCormick for Introducing Federal Biotech Leadership Legislation

July 24, 2026
July 24, 2026, Atlanta, GA - Georgia Life Sciences applauds Congressman Rich McCormick (R-GA) for introducing the Biotechnology Diplomacy Leadership Act , legislation designed to strengthen America's leadership in biotechnology by establishing a senior biotechnology leadership position within the U.S. Department of State. As biotechnology continues to drive breakthroughs in healthcare, agriculture, advanced manufacturing, and national security, the United States must remain a global leader in innovation while strengthening strategic partnerships with allies around the world. The proposed legislation recognizes biotechnology as a critical component of U.S. economic competitiveness and foreign policy and would help ensure that the federal government is well positioned to advance these priorities internationally. The legislation also reflects recommendations from the National Security Commission on Emerging Biotechnology , which called for a more coordinated national approach to advancing biotechnology and protecting U.S. leadership in this strategically important sector. "Georgia is home to one of the nation's fastest-growing life sciences ecosystems, and policies that strengthen America's global biotechnology leadership directly benefit innovators, researchers, manufacturers, and patients," said Maria Thacker Goethe, President & CEO of Georgia Life Sciences. "We appreciate Congressman McCormick's leadership in recognizing biotechnology as both an economic engine and a strategic national priority." Georgia Life Sciences looks forward to working with policymakers at both the federal and state levels to advance policies that foster innovation, strengthen the U.S. bioeconomy, and ensure America remains the global leader in biotechnology.

Georgia Life Sciences Names Renee' Martin, Ph.D., Program Manager to Lead Flagship Educator Workforce Development Program

July 21, 2026
Georgia Life Sciences names Renee Martin, Ph.D., to lead its Teacher Training Initiative, advancing educator workforce development and Georgia's future life sciences talent pipeline.
MORE POSTS